A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Latest Information Update: 09 Nov 2024
At a glance
- Drugs Temelimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ProTEct-MS
- Sponsors GeNeuro
Most Recent Events
- 13 Oct 2023 Results assessing paramagnetic rim lesions with soluble biomarker/imaging profiles and clinical features in a cohort of people with relapsing forms of MS (pwMS) with clinical worsening despite antiCD20 therapy presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 05 Apr 2023 According to a GeNeuro media release, ProTEct-MS study was performed in Stockholm, Sweden, at the Karolinska Institutet's Academic Specialist Center in Stockholm under the leadership of Prof. Fredrik Piehl.
- 28 Oct 2022 Primary endpoint (Safety and tolerability: adverse event) has been met according to results presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis